Ocrelizumab's effect on immune cells in lymph nodes in MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsing-remitting MS (RRMS) and can walk without help (EDSS score 0 to 5.5).
- You have never taken any MS medication before (treatment-naïve).
- Your MS symptoms started less than 15 years ago if your disability is more advanced.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You have no active infections, cancer, or other serious health conditions that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
This study looks at how well the injected form of ocrelizumab works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday care. It aims to understand the treatment's effects and side effects outside of a clinical trial setting.
This study looks at how ocrelizumab treatment affects a nerve health marker called neurofilament light chain (NfL) and how satisfied you are with the treatment. It may help doctors understand if this medicine works well for people with multiple sclerosis.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This trial tests an injectable medication called ocrelizumab for children and teenagers with relapsing-remitting multiple sclerosis. The goal is to see if it is safe and how well it works to control the disease.
Hear when a new Multiple Sclerosis, Relapsing-Remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.